Arrowhead Pharmaceuticals Q1 2025 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported a net loss of $173.085 million, or $1.39 per share, for the fiscal 2025 first quarter ended December 31, 2024. The company signed and closed a licensing and collaboration agreement with Sarepta Therapeutics and submitted its first NDA for investigational plozasiran.
Signed and closed a licensing and collaboration agreement with Sarepta Therapeutics, receiving $825 million upfront.
Submitted NDA for investigational plozasiran, which was accepted for filing by the U.S. FDA with a PDUFA action date of November 18, 2025.
Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026.
Initiated a Phase 1/2a clinical trial of ARO-INHBE for obesity and received regulatory clearance in New Zealand for a Phase 1/2a clinical trial of ARO-ALK7 for obesity.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
Arrowhead is currently funded into 2028 with further cash runway potential with multiple wholly owned candidates providing opportunities for additional partnerships. The company is now well positioned for growth with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years.
Positive Outlook
- Potential for multiple partner launches over the coming few years.
- Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026.
- Emerging high-value potential in obesity and CNS programs entering early clinical studies.
- Company is funded into 2028.
- Potential for additional partnerships.
Challenges Ahead
- Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $(173,085) thousand.
- Operating loss was $(161,412) thousand.
- Total cash resources decreased from $680,961 thousand to $552,935 thousand.
- Total Assets decreased from $1,139,802 thousand to $1,013,694 thousand.
- Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity decreased from $185,444 thousand to $52,589 thousand.